Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab vedotin in Japanese patients with urothelial carcinoma
NCT03070990Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Apr 2017
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enfortumab vedotin in urothelial carcinoma (UC) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Incidence of adverse events up to 12 months, Safety assessed by laboratory tests: Hematology up to 12 months and 11 more. Started Apr 2017; status: completed.
02
Drugs
enfortumab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03070990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070990.